|
Study
|
Histology
|
SCC (%)
|
Treatment
|
n
|
MS (months)
|
5-year OS (%)
|
P value
|
|---|
|
Launois and colleagues [11]
|
SCC
|
100
|
NART 40 Gy
|
77
|
10
|
10
|
NS
|
| | | |
Surgery
|
57
|
12
|
12
| |
|
Gignoux and colleagues [12]
|
SCC
|
100
|
NART 33 Gy
|
106
|
11
|
11
|
NS
|
| | | |
Surgery
|
102
|
11
|
10
| |
|
Arnott and colleagues [13]
|
AC/SCC
|
36
|
NART 20 Gy
|
90
|
8
|
9
|
NS
|
| | | |
Surgery
|
86
|
8
|
17
| |
|
Nygaard and colleagues [14]
|
SCC
|
100
|
NART 35 Gy
|
48
| |
21a
|
NS
|
| | | |
Surgery
|
41
| |
9a
| |
|
Wang and colleagues [15]
|
SCC
|
100
|
NART 40 Gy
|
104
| |
35
|
NS
|
| | | |
Surgery
|
102
| |
30
| |
- aThree-year overall survival (OS). AC adenocarcinoma, MS median survival, NART neoadjuvant radiotherapy, NS not significant, SCC squamous cell carcinoma.
